Paroxetine at bedtime
Paroxetine is first-line unless you take tamoxifen or already take an SSRI or SNRI. Brisdelle, the approved form, is 7.5 mg at bedtime.
Hot flashes start in the brain's temperature-control center. SSRIs such as paroxetine and SNRIs such as desvenlafaxine act on serotonin and norepinephrine signaling there, and both classes are recommended for hot flashes by The Menopause Society. Newer drugs target neurokinin receptors in the same circuit.
Falling estradiol triggers hot flashes, but the relief can come from the brain's side of the circuit. Hormone therapy is still the most effective option; these are the proven ones when it is not right for you.
How Gala's non-hormonal protocol usually runs. Onset timing is from The Menopause Society's 2023 nonhormone statement.
Paroxetine is first-line unless you take tamoxifen or already take an SSRI or SNRI. Brisdelle, the approved form, is 7.5 mg at bedtime.
SSRIs and SNRIs typically start working on hot flashes within 2 weeks.
Not enough relief or side effects? Your provider can switch to desvenlafaxine or adjust the plan.
Report mood changes right away; SSRIs carry a boxed warning about suicidal thoughts.
We ask the questions a thoughtful menopause clinician would. 5 minutes, no jargon.
A US-licensed clinician designs your protocol — pill or patch, progesterone if needed, vaginal estradiol if symptoms call for it.
Free shipping, dose adjustments and provider messaging are part of the plan.
Gala's providers start with paroxetine, the SSRI whose 7.5 mg form (Brisdelle) is FDA-approved for moderate to severe hot flashes. Paroxetine is skipped if you take tamoxifen, because it can weaken tamoxifen's effect, or if you already take an SSRI or SNRI. In those cases the protocol uses desvenlafaxine, an SNRI. Both classes are Level I recommendations in The Menopause Society's 2023 statement, typically working within 2 weeks.
Three non-hormonal drugs are FDA-approved specifically for moderate to severe hot flashes: Brisdelle (paroxetine 7.5 mg), Veozah (fezolinetant), which received a boxed warning for rare serious liver injury in December 2024, and Lynkuet (elinzanetant), approved in October 2025. Gala's protocol uses paroxetine or desvenlafaxine; your provider can explain how the others compare.
No. The Menopause Society's 2023 nonhormone statement says hormone therapy remains the most effective treatment for hot flashes. Non-hormonal medicines such as SSRIs and SNRIs are proven alternatives for women who cannot or prefer not to take hormones, and they do not replace estrogen's bone or vaginal benefits. Vaginal estrogen for dryness
There is no single best option. The Menopause Society gives its strongest recommendation to cognitive behavioral therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin and fezolinetant. Gala's providers start with paroxetine, or desvenlafaxine if paroxetine does not fit your medications.
Brisdelle (paroxetine 7.5 mg), Veozah (fezolinetant) and Lynkuet (elinzanetant) are FDA-approved for moderate to severe hot flashes. Veozah carries a boxed warning about rare serious liver injury.
Gala's protocol avoids paroxetine with tamoxifen, because paroxetine can reduce how well tamoxifen works. Your provider would use desvenlafaxine instead.
The Menopause Society's 2023 statement does not recommend herbal supplements or soy for hot flashes, because the evidence does not show they work reliably.
This page is general information, not medical advice. A licensed provider decides whether a treatment is right for you.